IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression
Cancer Letters · 2023-03 · 557 · 216075
DOI: 10.1016/j.canlet.2023.216075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023-03. Verfasst von Peng Xiao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150…. Hauptthemen laut MEDLINE: Cholangiocarcinoma. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
N6-methyladenosine (m6A) RNA methylation and its associated RNA-binding protein insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) are involved in tumor initiation and progression. Here, we explored the biological function and clinical significance of IGF2BP1 in intrahepatic cholangiocarcinoma (iCCA). We found that IGF2BP1 expression was upregulated by H3K27 acetylation enrichment of its promoter, which positively correlated with poor clinicopathological characteristics and survival. Gain- and loss-of-function experiments showed that IGF2BP1 overexpression (knockdown) enhanced (attenuated) iCCA growth and metastasis in vitro and in vivo. Mechanistically, IGF2BP1 not only regulated the c-Myc/p16 axis to promote iCCA growth and inhibit senescence, but also activated the ZIC2/PAK4/AKT/MMP2 axis to induce tumor metastasis. More importantly, BTYNB, a recently identified IGF2BP1 inhibitor, exerted promising anti-tumor efficacy in a patient-derived xenograft (PDX) model, and IGF2BP1 conditional knockout (cKO) reduced the tumor burden. These results demonstrate the crucial role of IGF2BP1 in iCCA progression via m6A-dependent modification, highlighting IGF2BP1 as a potential therapeutic target in iCCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China; Department of General Surgery, The First Affiliated Hospit…
- Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Xiao, P., Meng, Q., Liu, Q., Lang, Q., Yin, Z., Li, G., Li, Z., Xu, Y., Yu, Z., Geng, Q., Zhang, Y., Liu, L., Xie, Y., Li, L., Chen, H., Pei, T., & Sun, B. (2023). IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. Cancer Letters, 557, 216075. https://doi.org/10.1016/j.canlet.2023.216075
Vancouver
Xiao P, Meng Q, Liu Q, Lang Q, Yin Z, Li G, et al. IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. Cancer Letters. 2023;557:216075. doi:10.1016/j.canlet.2023.216075
BibTeX
@article{Xiao2023,
author = {Xiao, Peng and Meng, Qinghui and Liu, Qi and Lang, Qingfu and Yin, Zhijie and Li, Guanqun and Li, Zhibo and Xu, Yilin and Yu, Ze and Geng, Qi and Zhang, Yangyang and Liu, Liwei and Xie, Yu and Li, Le and Chen, Hua and Pei, Tiemin and Sun, Bei},
title = {IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression},
journal = {Cancer Letters},
year = {2023},
volume = {557},
pages = {216075},
doi = {10.1016/j.canlet.2023.216075}
}
EUVIMED